<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002621</url>
  </required_header>
  <id_info>
    <org_study_id>20-005018</org_study_id>
    <nct_id>NCT05002621</nct_id>
  </id_info>
  <brief_title>Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma</brief_title>
  <official_title>Exploratory Investigation of Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify gene transcripts after initiation of mepolizumab in&#xD;
      individuals with severe eosinophilic asthma (SEA), and to determine the composition of immune&#xD;
      cells present in the microenvironment of individuals with SEA after initiation of&#xD;
      mepolizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expressed gene transcripts</measure>
    <time_frame>Baseline and 4, 8, and 12 weeks post-initiation of mepolizumab</time_frame>
    <description>RNA sequencing will be performed from collected peripheral blood mononuclear cells (PBMCs) at four time points to compare changes in expressed gene transcripts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composition of immune cell subsets</measure>
    <time_frame>Baseline and 4, 8, and 12 weeks post-initiation of mepolizumab</time_frame>
    <description>CyTOF mass cytometry (50 test immune phenotype panel including cell surface markers, transcription factors, and cytokines) will be performed on PBMCs isolated from peripheral blood at four time points.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Eosinophilic Asthma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve twenty adult (≥18yo) individuals with a diagnosis of severe&#xD;
        eosinophilic asthma (SEA) who have been prescribed mepolizumab during their course of&#xD;
        routine clinical care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old.&#xD;
&#xD;
          -  Diagnosis of SEA by a health care provider&#xD;
&#xD;
          -  History of an absolute eosinophil count ≥ 300/mm^3&#xD;
&#xD;
          -  Prescription for mepolizumab provided during course of routine clinical care but&#xD;
             mepolizumab not yet started&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Currently using or have used within 3 months of the initial baseline visit any&#xD;
             biologic or immunomodulatory therapy with the exception of #3.&#xD;
&#xD;
          -  Currently using or any prior use of rituximab.&#xD;
&#xD;
          -  History of upper/lower respiratory tract infection or asthma exacerbation within the&#xD;
             previous four weeks of the first baseline visit.&#xD;
&#xD;
          -  Any prior history of malignancy, autoimmune disease, or immune deficiency.&#xD;
&#xD;
          -  Any other significant medical issue as determined by the principal investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanai Pongdee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Bachman, RN, CCRC</last_name>
      <phone>507-284-5689</phone>
      <email>bachman.kay@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Thanai Pongdee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

